ClinicalTrials.gg
RecruitingNCT05696873PICTUREUpdated May 8, 2024

CoPing strategIes-psyChological flexibiliTy in Patients Hospitalized for Ischemic cardiovascUlaR disEase (PICTURE)

An observational study in Ischemic Cardiovascular Disease, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Cardiocentro Ticino · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Stress, Psychological with a site in Switzerland — 2 open to participants now, 2 under way, none of them phase 3. Stress, Psychological · Switzerland.

Started
2023
the only one that year
Observational
5 of 17
1 open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Cardiocentro Ticino

Among the 17 studies in Stress, Psychological with a site in Switzerland, this one is the only one that started in 2023, is one of 5 observational ones, and was the 15th registered.

Stress, Psychological

854 studies on the registry are indexed under Stress, Psychological; 141 are open to participants now.

Browse Stress, Psychological studies →

Open to participants now

2 of the 17 studies in Stress, Psychological with a site in Switzerland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 74 Stress, Psychological studies recruiting now, 34 (46%) set no upper age limit and 36 (49%) stop at 75 or younger; 13 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Stress, Psychological with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of this trial is to investigate the coping strategies/physiological flexibility construct in patients hospitalized for ischemic cardiovascular disease and the possible association with recurrence of clinical events (any hospitalization and type thereof, myocardial infarction, stroke and death) during the follow up, the patient's decision to participate to clinical trials approved in the center and the adherence to cardiovascular medications.

03

Conditions studied

  • Ischemic Cardiovascular Disease

Browse trials for

Keywords

  • ischemic cardiovascular disease
  • mental stress
  • coping strategies
  • patient's decision to partecipate to clinical trial
  • adherence to the medications
  • psychological flexibility
  • acceptance and commitment therapy
  • hexaflex
  • Brief Cope test
  • MPFI test
  • CFQ test
  • MAAS-8 test
  • CVD-AAQ test
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with age ≥ 18 years old and admission to the hospital for ischemic cardiovascular disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Able to provide
  • Able to speak and read in the local language spoken in hospital
  • Admission to the hospital for ischemic cardiovascular disease

Exclusion criteria

Exclusion Criteria:

  • Cannot provide written
  • Under judicial protection, tutorship or curatorship
  • Unable to understand and follow study-related instructions or unable to comply with study protocol
  • Cognitive impairment
  • Severe psychiatric disorders according to criteria diagnosed in the last 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. coping strategies and the recurrence of any hospitalization and type thereof, myocardial infarction, stroke and death during the follow up period (2 years±14 days from index hospitalization)

    coping strategies (evaluated using Brief COPE test) and the recurrence of clinical events (any hospitalization and type thereof, myocardial infarction, stroke and death) during the follow up period (2 years±14 days from index hospitalization)

    Time frame: 2 years (±14 days) from index hospitalization

  2. psychological flexibility and the recurrence any hospitalization and type thereof, myocardial infarction, stroke and death during the follow up period (2 years±14 days from index hospitalization)

    psychological flexibility construct (evaluated using MPFI test - Multidimensional Psychological Flexibility Inventory test and CFQ test - Cognitive Fusion Questionnaire) and the recurrence of clinical events (any hospitalization and type thereof, myocardial infarction, stroke and death) during the follow up period (2 years±14 days from index hospitalization)

    Time frame: 2 years (±14 days) from index hospitalization

  3. coping strategies and the patient's decision to participate to the clinical trials approved in the centres

    coping strategies (evaluated using Brief COPE test) and the patient's decision to participate to the clinical trials approved in the centres

    Time frame: at discharge of index hospitalization (up to 4 weeks)

  4. psychological flexibility and the patient's decision to participate to the clinical trials approved in the centres

    psychological flexibility construct (evaluated using MPFI test - Multidimensional Psychological Flexibility Inventory test and CFQ test - Cognitive Fusion Questionnaire) and the patient's decision to participate to the clinical trials approved in the centres

    Time frame: at discharge of index hospitalization (up to 4 weeks)

  5. coping strategies and the adherence to cardiovascular medications

    coping strategies (evaluated using Brief COPE test) and the adherence to cardiovascular medications

    Time frame: 2 years (±14 days) from index hospitalization

  6. psychological flexibility and the adherence to cardiovascular medications

    psychological flexibility construct (evaluated using MPFI test and - Multidimensional Psychological Flexibility Inventory test and CFQ test - Cognitive Fusion Questionnaire) and the adherence to cardiovascular medications

    Time frame: 2 years (±14 days) from index hospitalization

Secondary outcomes

  1. each coping strategy and the recurrence of any hospitalization and type thereof, myocardial infarction, stroke and death

    each coping strategy (evaluated using Brief COPE test) and the recurrence of clinical events type (any hospitalization and type thereof, myocardial infarction, stroke and death)

    Time frame: 2 years (±14 days) from index hospitalization

  2. each component of psychological flexibility model and the recurrence of any hospitalization and type thereof, myocardial infarction, stroke and death

    each component of psychological flexibility model (evaluated using MPFI test - Multidimensional Psychological Flexibility Inventory test and CFQ test - Cognitive Fusion Questionnaire) and the recurrence of clinical events type (any hospitalization and type thereof, myocardial infarction, stroke and death)

    Time frame: 2 years (±14 days) from index hospitalization

  3. each coping strategy (evaluated using Brief COPE test) and the participation to each proposed clinical trial, with a particular focus on the SOS-AMI trial

    each coping strategy (evaluated using Brief COPE test) and the participation to each proposed clinical trial, with a particular focus on the SOS-AMI trial, since it requires copying with the patient decision to self-administer treatment unlike other studies in which treatment is physician-directed

    Time frame: at discharge of index hospitalization (up to 4 weeks)

  4. each component of psychological flexibility and the participation to each proposed clinical trial, with a particular focus on the SOS-AMI trial

    each component of psychological flexibility construct (evaluated using MPFI test and - Multidimensional Psychological Flexibility Inventory test and CFQ test - Cognitive Fusion Questionnaire) and the participation to each proposed clinical trial, with a particular focus on the SOS-AMI trial, since it requires copying with the patient decision to self-administer treatment unlike other studies in which treatment is physician-directed

    Time frame: at discharge of index hospitalization (up to 4 weeks)

  5. cognitive fusion and recurrence of cardiovascular events

    cognitive fusion (evaluated using CFQ test - Cognitive Fusion Questionnaire) and recurrence of cardiovascular events

    Time frame: at 2 years (±14 days) from index hospitalization

  6. cognitive fusion and participation to the trials

    cognitive fusion (evaluated using CFQ test - Cognitive Fusion Questionnaire) and participation to the trials

    Time frame: at discharge of index hospitalization (up to 4 weeks)

  7. cognitive fusion and adherence to cardiovascular medications

    cognitive fusion (evaluated using CFQ test - Cognitive Fusion Questionnaire) and adherence to cardiovascular medications

    Time frame: at 2 years (±14 days) from index hospitalization

  8. psychological flexibility evaluated with CVD-AAQ test and cardiovascular events

    psychological flexibility evaluated with CVD-AAQ test (Cardiovascular Disease Acceptance and Action Questionnaire) and cardiovascular events

    Time frame: at 2 years (±14 days) from index hospitalization

  9. psychological flexibility evaluated with CVD-AAQ test and participation to the trials

    psychological flexibility evaluated with CVD-AAQ test (Cardiovascular Disease Acceptance and Action Questionnaire) and participation to the trials

    Time frame: at discharge of index hospitalization (up to 4 weeks)

  10. psychological flexibility evaluated with CVD-AAQ test and adherence to cardiovascular medications

    psychological flexibility evaluated with CVD-AAQ test (Cardiovascular Disease Acceptance and Action Questionnaire) and adherence to cardiovascular medications

    Time frame: at 2 years (±14 days) from index hospitalization

07

Study locations

1 of 1 sites recruiting
  • Enrico Frigoli
    Lugano, 6900, Switzerland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.

Of 60 non-industry observational studies under Stress, Psychological, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 57. This study's planned 34 months is above that.

Counting every sponsor, half of 64 studies reached it within 23 months; a quarter within 6 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 25, 2023
StartActual
Feb 9, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05696873
Lead sponsor
Cardiocentro Ticino
Responsible party
Marco Valgimigli (Deputy Chief, Cardiocentro Ticino) — Principal investigator
First posted
Jan 25, 2023
Start date
Feb 9, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 8, 2024

Study contacts

Marco Valgimigli, M.D., Ph.D
Contact
marco.valgimigli@eoc.ch
+410918115111
enrico frigoli, M.D.
Contact
enricofrigoli@gmail.com
Marco Valgimigli, M.D., Ph.D
principal investigator · Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano,

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion